Overview

Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2028-11-30

Target enrollment:

Participant gender:

Summary

This research study is being done to determine the rate of testosterone recovery after completing two years of treatment with the combination of relugolix and darolutamide as well as to assess the safety of the drugs when administered in combination. The names of the drugs in this study are: * Relugolix (a type of gonadotropin-releasing hormone receptor antagonist) * Darolutamide (a type of androgen receptor antagonist)

Phase:

PHASE2

Details

Lead Sponsor:

Atish Choudhury, MD

Collaborators:

Bayer
National Comprehensive Cancer Network
Pfizer
Sumitomo Pharmaceuticals America

Treatments:

darolutamide
relugolix